SAB Biotherapeutics, Inc.
SABS
$3.94
-$0.21-5.06%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -92.42% | -95.87% | -85.48% | -40.94% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -92.42% | -95.87% | -85.48% | -40.94% |
| Cost of Revenue | -24.25% | 50.64% | 27.72% | 116.35% | 166.60% |
| Gross Profit | 21.90% | -62.51% | -44.48% | -146.32% | -199.15% |
| SG&A Expenses | 7.73% | -51.39% | -50.56% | -45.37% | -39.15% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 10.67% | -18.73% | -13.65% | -4.47% | 9.72% |
| Operating Income | -14.08% | 16.58% | 8.66% | -0.54% | -12.70% |
| Income Before Tax | 138.92% | 141.13% | 8.10% | 14.02% | 19.17% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 138.92% | 141.13% | 8.10% | 14.02% | 19.17% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 138.92% | 141.13% | 8.10% | 14.02% | 19.17% |
| EBIT | -14.08% | 16.58% | 8.66% | -0.54% | -12.70% |
| EBITDA | -20.34% | 14.39% | 5.64% | -3.89% | -11.03% |
| EPS Basic | 117.15% | 90.82% | 62.14% | 40.99% | 48.73% |
| Normalized Basic EPS | 161.53% | 123.81% | 29.87% | 40.98% | 48.73% |
| EPS Diluted | 92.58% | 78.56% | 62.06% | 40.91% | 48.66% |
| Normalized Diluted EPS | 61.56% | 60.76% | 29.87% | 40.98% | 48.73% |
| Average Basic Shares Outstanding | 108.51% | 11.66% | 21.78% | 41.13% | 67.76% |
| Average Diluted Shares Outstanding | 289.90% | 206.36% | 21.78% | 41.13% | 67.76% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |